A Study of ARC-02 in B-cell NHL (NCT07691606)
A Study to Evaluate Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity of ARC-02 in Adult Participants With B-cell Non-Hodgkins Lymphoma (NHL)
🩺 Plain-English Summary (8th-Grade Level)
This study is to assess safety, tolerability, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of ARC-02.
Who can join: Review the eligibility criteria below.
Location: Start Cala — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (29 Sites)
Showing the first 25 of 29 sites.
- Start Cala — Los Angeles, California
- Norton Cancer Institute — Louisville, Kentucky
- NYU Langone — New York, New York
- Levine Cancer Institute — Charlotte, North Carolina
- Massey Cancer Center — Richmond, Virginia
- Summit Cancer Centers - North Spokane — Spokane, Washington
- Froedtert & Medical College of Wisconsin — Milwaukee, Wisconsin
- Monash Health — Clayton,
- Austin Health — Melbourne,
- Linear Clinical Research — Nedlands,
- Gold Coast Hospital — Southport,
- Hopital Henri-Mondor — Créteil,
- Centre Hospitalier Universitaire de Lille (CHU Lille) - Hopital Claude Huriez — Lille,
- Hôpital Lyon Sud — Lyon,
- CHU Nantes - Hotel Dieu — Nantes,
- Institut Gustave Roussy — Villejuif,
- Centro di Riferimento Oncologico (CRO Aviano) — Aviano,
- ASST Papa Giovanni XXIII — Bergamo,
- University of Bologna — Bologna,
- Istituto Clinico Humanitas — Rozzano,
- Pratia Onkologia Katowice — Katowice,
- Pratia MCM Krakow — Krakow,
- Szpital AidPort — Skorzewo,
- Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy — Warsaw,
- Hospital Universitari Vall d'Hebron — Barcelona,
📞 Contact the Study Coordinator
Phone: (844) 878-2446
Email: medicalinformation@taihooncology.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in B-cell Non Hodgkin Lymphoma
- A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma — Tampa, Florida
- Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies — Milwaukee, Wisconsin
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL — Charleston, South Carolina
Explore by condition: All B-cell Non Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.